Dr Reddy’s Lab gets inspection closure report for Miryalaguda plant; stock up 1%

The company has received the Establishment Inspection Report (EIR) from USFDA, for the facility, indicating closure of the audit and the inspection classification of this facility is determined as Voluntary Action Initiated.

May 31, 2019 03:05 IST India Infoline News Service

Dr Reddy Lab
Shares of Dr Reddy’s Lab gained 1% in the early morning trade on Friday. The company has received the Establishment Inspection Report (EIR) from USFDA, for  Miryalaguda plant, indicating closure of the audit and the inspection classification of this facility is determined as Voluntary Action Initiated (VAI).

“Further to our intimation dated January 28, 2019 with regard to the audit of our API manufacturing plant at Miryalaguda (Nalgonda District), we would like to inform you that we have received the Establishment Inspection Report (EIR) from USFDA, for the above-referred facility, indicating closure of the audit and the inspection classification of this facility is determined as Voluntary Action Initiated (VAI),” the company said in the filing aftermarket hours on Thursday.

Dr Reddys Laboratories Ltd is currently trading at Rs2,675, up by Rs23.6 or 0.89%, from its previous close of Rs2,651.40 on the BSE.

The scrip opened at Rs2,663.10 and has touched a high and low of Rs2,688.45 and Rs2,660, respectively.

Related Story